phrykt

Sutro Biopharma, Inc. (STRO): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of STRO were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Sutro Biopharma

From the latest filings

Overall: about as much buying as selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns STRO

98 funds and institutions reported STRO shares worth $548M at the end of Q2 2026, about 100% of the company. The largest holder is Perceptive Advisors LLC with 7.9%.

Funds and institutions (13F) 100%Everyone else 0%

10 largest owners, by share of the company

Perceptive Advisors LLC7.9%
Bvf Inc7.6%
Affinity Asset Advisors, LLC7.1%
BlackRock, Inc.6.8%
Samsara Biocapital, LLC6.4%
Kynam Capital Management, LP5.3%
Orbimed Advisors LLC4.5%
Balyasny Asset Management L.P.4.3%
Vanguard Capital Management LLC4.2%
Eventide Asset Management, LLC3.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Perceptive Advisors LLC1.30M7.88%$43.3M+82%
Bvf Inc1.25M7.56%$41.6MNo change
Affinity Asset Advisors, LLC1.17M7.08%$38.9M+10%
BlackRock, Inc.1.12M6.78%$37.3M+382%
Samsara Biocapital, LLC1.06M6.42%$35.3MNo change
Kynam Capital Management, LP872,5585.27%$29MNo change
Orbimed Advisors LLC743,9444.49%$24.7M-7%
Balyasny Asset Management L.P.711,1624.29%$23.6M+53%
Vanguard Capital Management LLC694,2194.19%$23M-4%
Eventide Asset Management, LLC585,2623.53%$19.4M-18%
Velan Capital Investment Management LP512,1603.09%$17MNo change
Woodline Partners LP458,0292.76%$15.2M+0%
ADAR1 Capital Management, LLC404,0142.44%$13.4M-23%
Geode Capital Management, LLC389,6922.35%$12.9M+127%
Acadian Asset Management LLC373,8392.26%$12.4M+11%
Millennium Management LLC365,9722.21%$12.2M+74%
State Street Corp305,9791.85%$10.2M+487%
Merck & Co., Inc.272,3511.64%$9MNew
Acuta Capital Partners, LLC270,2511.63%$9M+0%
Ameriprise Financial Inc244,6691.48%$8.1MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No STRO insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

STRO short interest

High short interest. 13.6% of STRO shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 89%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.26M STRO shares were sold short, 13.6% of the shares outstanding, up 15.1% from the report before. At the average daily volume of 360,485 shares, buying them all back would take about 6.3 trading days (days to cover).

Shares short, % of all shares

13.6%May 15Oct 3015.0%

Days to cover

6.3May 15Oct 309.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.26M13.61%+15%360,4856.3
Oct 15, 20261.96M11.83%+6%313,0776.3
Sep 30, 20261.85M11.14%-11%285,3226.5
Sep 15, 20262.08M12.52%+15%346,6106.0
Aug 31, 20261.81M10.91%-2%212,0308.5
Aug 14, 20261.86M11.19%+6%344,5745.4
Jul 31, 20261.74M10.53%+6%274,7606.3
Jul 15, 20261.65M9.98%+21%370,5854.5
Jun 30, 20261.36M8.22%+48%590,7962.3
Jun 15, 2026922,1885.57%+23%236,2083.9
May 29, 2026751,3654.54%-37%434,2011.7
May 15, 20261.19M7.20%+22%212,7735.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Sutro Biopharma company events

Sutro Biopharma filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 12, 2026.

  1. Aug 12, 2026ResultsReleased financial results. Filing
  2. Jun 8, 2026VoteReported shareholder vote results. Filing
  3. May 14, 2026ResultsReleased financial results. Filing
  4. Mar 23, 2026AgreementEnded an important agreement. Filing
  5. Feb 10, 2026AgreementSutro Biopharma, Inc. entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell 7,868,383 shares of its common stock to the Underwriters. Filing
  6. Dec 17, 2025AnnouncementSutro Biopharma, Inc. received notice from the Listing Qualifications staff of the Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1). Filing
  7. Dec 3, 2025AnnouncementThe Board approved the Reverse Stock Split at a ratio of 1-for-10. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Sutro Biopharma financials

Famous investors that hold STRO

5 of the 50 well-known investors we track reported holding STRO in their latest 13F filing. The largest position is Ken Griffin's, worth $4.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026289,939$4.7M0.0%+184%
Steve Cohen · Point72 Asset ManagementQ3 2026136,793$2.2M0.0%-42%
Jim Simons · Renaissance TechnologiesQ3 202687,247$1.4M0.0%+1%
Ken Fisher · Fisher Asset ManagementQ3 202635,295$569K0.0%No change
Israel Englander · Millennium ManagementQ3 202624,754$399K0.0%-93%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named STRO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Perceptive Advisors LLC13G/A5.8%
Nov 16, 2026Perceptive Advisors LLC13G/A5.8%
Nov 9, 2026Coastlands Capital LP13G5.1%
Nov 9, 2026Coastlands Capital LP13G5.1%

Questions about Sutro Biopharma, Inc. (STRO) stock

Who owns the most STRO stock?

The largest reported owner of Sutro Biopharma, Inc. (STRO) is Perceptive Advisors LLC, with 7.9% of the company. In total, 98 funds and institutions reported holding STRO at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are STRO insiders buying or selling?

No STRO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in STRO?

As of Oct 30, 2026, 2.26M STRO shares were sold short, 13.6% of the shares outstanding, up 15.1% from the report before. At the average daily volume of 360,485 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.

Which famous investors hold STRO?

5 of the 50 well-known investors we track reported STRO in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $4.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.